Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib in Pediatric FLT3-ITD+ and NPM1wt AML
NCT06262438Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Feb 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of quizartinib in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Started Feb 2024; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06262438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06262438.